FABP4 interacts with PPARγ to promote malignant progression in pancreatic cancer.

Chen-Xi Yang, Cun-Xia Li, Qian Zhang, Jing Yun, Hui Wang, Jian Huangfu, Jian-Jun Ren, Rui Xiao

Abstract read

In one paragraph

Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chen-Xi YangInner Mongolia Key Laboratory of Molecular Pathology, Inner Mongolia Medical University, Huhhot 010059, China.

Cun-Xia LiDepartment of Endocrinology, the Affiliated Hospital of Inner Mongolia Medical University, Huhhot 010051, China.

Qian ZhangDepartment of Hepatobiliary, Pancreatic and Splenic Surgery, the Affiliated Hospital of Inner Mongolia Medical University, Huhhot 010051, China.

Jing YunInner Mongolia Key Laboratory of Molecular Pathology, Inner Mongolia Medical University, Huhhot 010059, China.

Hui WangDepartment of Endocrinology, the Affiliated Hospital of Inner Mongolia Medical University, Huhhot 010051, China.

Jian HuangfuDepartment of Endocrinology, the Affiliated Hospital of Inner Mongolia Medical University, Huhhot 010051, China.

Jian-Jun RenDepartment of Hepatobiliary, Pancreatic and Splenic Surgery, the Affiliated Hospital of Inner Mongolia Medical University, Huhhot 010051, China.

Rui XiaoInner Mongolia Key Laboratory of Molecular Pathology, Inner Mongolia Medical University, Huhhot 010059, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive malignancy with an exceptionally poor prognosis. Fatty acid-binding protein 4 (FABP4) has been implicated in tumorigenesis and peroxisome proliferator-activated receptor γ (PPARγ) signaling, but its precise functional role and underlying molecular mechanisms in PDAC remain poorly defined. Here, we showed that FABP4 is markedly upregulated in pancreatic cancer cells. Co-immunoprecipitation assays revealed an interaction between FABP4 and PPARγ, and FABP4 overexpression significantly enhanced pancreatic cancer cell viability, proliferation, and migratory capacity

Indexed as

FABP4fatty acid-binding protein 4lipid metabolismpancreatic ductal adenocarcinomaperoxisome proliferator-activated receptor gammaPPARγ

Identifiers

PMID42491919

DOI10.1016/j.isci.2026.116547

PMCPMC13378347

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC-ND

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.